Marshall Wace, LLP Immunocore Holdings PLC Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 28,610 shares of IMCR stock, worth $840,275. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,610
Previous 199,443
85.66%
Holding current value
$840,275
Previous $6.21 Million
86.42%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding IMCR
# of Institutions
125Shares Held
42.5MCall Options Held
79.9KPut Options Held
46.2K-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.7MShares$197 Million0.12% of portfolio
-
Wellington Management Group LLP Boston, MA6.62MShares$194 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY4.87MShares$143 Million2.34% of portfolio
-
Primecap Management CO Pasadena, CA2.67MShares$78.4 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.19MShares$64.2 Million0.01% of portfolio
About Immunocore Holdings plc
- Ticker IMCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,897,100
- Market Cap $1.29B
- Description
- Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...